Walk through any peptide catalogue and you'll notice something odd about Semax: the product most often listed isn't Semax. It's "N-Acetyl Semax Amidate" — a chemically capped version of the original heptapeptide, usually priced higher and described as a stronger, longer-lasting upgrade. Almost the entire published Semax research literature, including the Russian clinical work, was done on the uncapped molecule. This post looks at what the capping actually does, the one published experiment that compared the two head-to-head, and where both sit under Australian law.

For the background profile, see our Semax page; for the wider library, /peptides.

What is Semax, and what is the amidate version?

Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues come from the ACTH(4–7) fragment of adrenocorticotropic hormone; the Pro-Gly-Pro tail is a synthetic addition. That tail exists for one reason: bare ACTH fragments are shredded by blood peptidases within minutes, and the glyproline tail slows that down enough for the molecule to be usable as a nasal drug. Despite the ACTH lineage, Semax is not reported to drive cortisol release — the melanocortin fragment retained is the behaviourally active part, not the steroidogenic one.

N-Acetyl Semax Amidate takes that same sequence and blocks both ends: an acetyl group on the N-terminal amine, an amide in place of the C-terminal carboxyl. Exopeptidases chew inwards from the termini, so capping both ends is a textbook way to extend a peptide's life. The chemistry is sound. The inference — that a longer-lived molecule is a better-working molecule — is where the evidence thins out.

The stability argument is a hypothesis, not a result

Rodent work established the basic picture for plain Semax: rapid N-terminal degradation in blood, yet detectable brain exposure after intranasal dosing, because the nasal route delivers along olfactory and trigeminal pathways rather than relying on systemic circulation. That's the pharmacological logic behind the registered Russian nasal drops.

What doesn't exist, publicly, is the equivalent dataset for the capped analogue: no published human pharmacokinetics, no comparative brain-exposure study, no clinical trial. There are no internationally registered trials of Semax in any form, and none we can find of the amidate. Every "lasts longer, hits harder" claim attached to the capped version is extrapolation from general peptide chemistry, not measurement of this specific compound.

The one experiment that tested a capped Semax

There is a direct comparison in the literature, and it points the other way.

A 2016 study in the Journal of Inorganic Biochemistry examined N-terminally acetylated Semax alongside ordinary Semax, focusing on how each binds copper(II) and zinc(II). Zinc binding was comparable between the two. Copper was not. The free N-terminal amine is a key anchor for Cu(II) coordination, and acetylating it changed the complexes formed and their redox behaviour. In SH-SY5Y neuroblastoma cells, the acetylated peptide did not protect against copper-induced toxicity, while the parent peptide did — the authors attributed this to the crucial role of the free NH₂ terminus.

Why does a metal-binding assay matter for a nootropic? Because that mechanism has since been pursued further. A 2025 paper in Bioinorganic Chemistry and Applications reported that Semax strips copper from amyloid-beta complexes and "redox silences" it, cutting Cu(II)-catalysed reactive-oxygen-species production and protecting SH-SY5Y cells — a mechanism the authors describe as independent of Semax's neurotrophic effects.

State it plainly: both are in vitro studies, in one cell line, on narrow endpoints, and unreplicated in animals or humans. The 2016 paper tested acetylation only, not the acetyl-plus-amide combination sold commercially. It is not proof that N-Acetyl Semax Amidate is inferior. It is, however, the only published head-to-head evidence on a capped Semax, and it shows that capping a terminus can cost you an activity rather than only buying stability.

The tail that gets cut off is itself active

There's a second wrinkle. Pro-Gly-Pro isn't inert packaging. It's a glyproline — a class of short peptides found in collagen breakdown products with documented biological activity of their own. Work published in the Bulletin of Experimental Biology and Medicine reported that both Semax and its Pro-Gly-Pro fragment delayed calcium dysregulation and loss of mitochondrial potential in cultured cerebellar granule cells under glutamate stress, improving survival.

If part of Semax's effect is delivered by its own degradation product, then engineering the molecule to degrade less — and amidating the very carboxyl terminus that releases free PGP — is not unambiguously an improvement. Nobody has tested this directly. It's a mechanistic question the marketing copy skips entirely.

Semax Australia: is Semax legal in Australia?

The regulatory position is the same for the plain and capped forms, and it isn't ambiguous.

Semax is unscheduled in the Poisons Standard — which people routinely misread as "approved". It isn't. Semax has no ARTG registration, which makes it an unapproved therapeutic good: importing or supplying it in Australia outside a TGA pathway (such as the Special Access Scheme, Authorised Prescriber arrangements, or a clinical trial notification) is unlawful. "Research use only" labelling doesn't alter that, and neither does adding acetyl and amide caps.

Where it is registered is Russia, as intranasal drops, and it appears on Russia's Vital and Essential Drugs list. That registration covers the original heptapeptide — not N-Acetyl Semax Amidate, which is registered nowhere.

For athletes: Semax is not named on the WADA 2026 Prohibited List, but anti-doping specialists describe its status as unclear rather than cleared, given the breadth of the catch-all categories. Anyone tested competitively should treat it as a live risk, not a settled one.

What would actually change the picture

Three things, none of which currently exist publicly: a comparative pharmacokinetic study of capped versus uncapped Semax in a living animal; any behavioural or cognitive endpoint measured for the amidate form; and replication of the Russian clinical work outside its original research ecosystem. Until then, the honest summary is that the modified version inherits the parent molecule's reputation without inheriting its evidence.

Want these breakdowns as they're published? Join the free updates list.

FAQ

What is N-Acetyl Semax Amidate?

It's Semax with both ends chemically capped — an acetyl group on the N-terminus and an amide on the C-terminus — intended to slow enzymatic breakdown. It's a modified analogue, not the molecule used in the published Semax research.

Is Semax legal in Australia?

Semax is unscheduled in the Poisons Standard but has no ARTG registration, making it an unapproved therapeutic good. Importing or supplying it outside a TGA pathway such as the Special Access Scheme is unlawful.

Is N-Acetyl Semax Amidate stronger than Semax?

There's no published human or animal evidence showing it is. The one in vitro study comparing acetylated Semax with the parent peptide found the acetylated version lost protection against copper-induced cell toxicity.

Is Semax banned by WADA?

Semax is not named on the WADA 2026 Prohibited List, but anti-doping specialists rate its status as unclear rather than permitted, so tested athletes shouldn't treat its absence as clearance.

Sources

Not medical advice. Semax is not approved by the TGA and is an unapproved therapeutic good in Australia; retatrutide.net.au is independent, sells nothing, and does not direct readers to suppliers.